Hudson Capital Management LLC grew its holdings in Amgen, Inc. (NASDAQ:AMGN) by 5.4% during the 3rd quarter, according to the company in its most recent filing with the SEC. The fund owned 8,133 shares of the medical research company’s stock after purchasing an additional 414 shares during the period. Amgen makes up about 1.3% of Hudson Capital Management LLC’s portfolio, making the stock its 19th biggest position. Hudson Capital Management LLC’s holdings in Amgen were worth $1,686,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also modified their holdings of the company. Beutel Goodman & Co Ltd. bought a new stake in Amgen during the 2nd quarter worth $86,723,000. Mutual Advisors LLC grew its position in Amgen by 5.8% during the 2nd quarter. Mutual Advisors LLC now owns 4,814 shares of the medical research company’s stock worth $889,000 after acquiring an additional 265 shares during the last quarter. Schwab Charles Investment Management Inc. grew its position in Amgen by 2.3% during the 2nd quarter. Schwab Charles Investment Management Inc. now owns 3,207,242 shares of the medical research company’s stock worth $592,025,000 after acquiring an additional 72,205 shares during the last quarter. Perpetual Ltd grew its position in Amgen by 10.3% during the 2nd quarter. Perpetual Ltd now owns 8,554 shares of the medical research company’s stock worth $1,582,000 after acquiring an additional 800 shares during the last quarter. Finally, Argent Trust Co grew its position in Amgen by 31.8% during the 2nd quarter. Argent Trust Co now owns 11,691 shares of the medical research company’s stock worth $2,159,000 after acquiring an additional 2,818 shares during the last quarter. Institutional investors own 82.48% of the company’s stock.

A number of equities research analysts recently weighed in on the company. Royal Bank of Canada restated a “neutral” rating and set a $193.00 price objective on shares of Amgen in a research report on Monday, September 10th. Goldman Sachs Group set a $229.00 price objective on Amgen and gave the stock a “buy” rating in a research report on Friday. Piper Jaffray Companies boosted their price objective on Amgen from $190.00 to $210.00 and gave the stock an “overweight” rating in a research report on Thursday, July 26th. They noted that the move was a valuation call. BidaskClub upgraded Amgen from a “buy” rating to a “strong-buy” rating in a research report on Wednesday, July 11th. Finally, Cann restated a “buy” rating and set a $224.00 price objective on shares of Amgen in a research report on Monday, July 30th. One analyst has rated the stock with a sell rating, thirteen have issued a hold rating and eleven have assigned a buy rating to the company’s stock. Amgen currently has an average rating of “Hold” and a consensus target price of $204.90.

NASDAQ AMGN opened at $197.39 on Friday. Amgen, Inc. has a 12 month low of $163.31 and a 12 month high of $210.19. The stock has a market capitalization of $134.17 billion, a price-to-earnings ratio of 15.69, a P/E/G ratio of 2.02 and a beta of 1.40. The company has a debt-to-equity ratio of 2.03, a quick ratio of 3.12 and a current ratio of 3.39.

Amgen (NASDAQ:AMGN) last released its quarterly earnings results on Thursday, July 26th. The medical research company reported $3.83 EPS for the quarter, beating analysts’ consensus estimates of $3.52 by $0.31. Amgen had a return on equity of 43.18% and a net margin of 10.19%. The firm had revenue of $6.06 billion for the quarter, compared to analyst estimates of $5.73 billion. During the same quarter in the previous year, the company posted $3.27 EPS. The business’s revenue was up 4.3% on a year-over-year basis. Equities research analysts expect that Amgen, Inc. will post 13.96 EPS for the current year.

In other news, EVP Sean E. Harper sold 1,525 shares of the business’s stock in a transaction dated Monday, July 16th. The stock was sold at an average price of $195.71, for a total value of $298,457.75. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Insiders own 0.27% of the company’s stock.

Amgen Company Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. It offers products for the treatment of oncology/hematology, cardiovascular, inflammation, bone health, nephrology, and neuroscience. The company's products include Evenity to treat osteoporosis in postmenopausal women; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Repatha to treat coronary diseases; Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Parsabiv to treat secondary hyperparathyroidism (sHPT); and Aimovig for the prevention of migraine.

Further Reading: Understanding Compound Annual Growth Rate (CAGR)

Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen, Inc. (NASDAQ:AMGN).

Institutional Ownership by Quarter for Amgen (NASDAQ:AMGN)

Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.